Hypofractionated Radiation Therapy: clinical trials recruiting now

Phase breakdown

Conditions being studied

Recruiting trials involving Hypofractionated Radiation Therapy

• An Evaluation of Dose-escalation for Intrathoracic Tumours
  NCT06794125 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Hypofractionated Post-prostatectomy Radiotherapy (HYPORT)for Localized Prostate Cancer
  NCT06325995 · Phase: Not applicable (e.g. observational or device study) · Ages: No age limits stated · Sex: Male · 1 location
• Hypofractionated Radiation Fractionation in Breast Cancer Patients With Implant-Based Reconstruction
  NCT06830083 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: Female · 1 location
• Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
  NCT06635980 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer
  NCT06984250 · Phase: Not specified · Ages: 20 Years to 85 Years · Sex: Female · 2 locations
• Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC
  NCT07052669 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
  NCT04318717 · Phase: Phase 2 · Ages: 16 Years and older · Sex: All (male and female) · 1 location
• Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation
  NCT06110572 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Radical Hypofractionated Radiotherapy for Localized Prostate Cancer
  NCT06325774 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Male · 1 location
• SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
  NCT06205316 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 6 locations
• Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
  NCT04172532 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 44 locations

Common questions

How many recruiting trials involve Hypofractionated Radiation Therapy?

11 recruiting trials across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.